Procept Biorobotics Corp (PRCT)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.37B
Last updated: Nov 17, 2026 at 4:38 PM ET
Procept Biorobotics Corp (PRCT) Statistics
Procept Biorobotics (PRCT) has a market cap of $1.37B and an enterprise value of $1.20B. It kept -32.60% of revenue as net income over the last 12 months. It holds $166.60M more cash than debt, 12.17% of its market cap.
Total Valuation
Enterprise value is 12.17% below the market cap, as cash exceeds debt.
| Market Cap | $1.37B |
|---|---|
| Enterprise Value | $1.20B |
| Latest price (Nov 17, 2026) | $23.78 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.9x and 4.1x. Its year-end P/S ranged from 5.7x to 24.6x from 2021 to 2025.
| P/S Ratio | 3.9x |
|---|---|
| Forward P/S | 3.5x |
| P/B Ratio | 4.1x |
| P/TBV Ratio | 4.2x |
Price Statistics
The stock is down 19.91% over 52 weeks and trades 21.45% above its 50-day average.
| Beta (1Y) | 0.97 |
|---|---|
| 52-Week Change | -19.91% |
| 1-Month Change | +30.09% |
| 3-Month Change | +8.53% |
| 6-Month Change | -8.22% |
| 5-Year Change | -55.07% |
| Total Return (1Y) | -19.91% |
| Total Return (3Y CAGR) | -10.40% |
| Total Return (5Y CAGR) | -10.34% |
| Return vs SPY (1Y) | -27.83% |
| Max Drawdown (1Y) | -53.77% |
| Max Drawdown (3Y) | -83.22% |
| Sharpe Ratio (1Y) | -0.27 |
| Correlation with SPY (1Y) | 0.20 |
| 50-Day Average | $19.58 |
| 200-Day Average | $22.85 |
| 52-Week Range | $16.66 to $38.11 |
| RSI (14 Days) | 67.9 |
| Average Volume (20 Days) | 1.34M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.89x current liabilities, and total debt is 0.16x shareholder equity.
| Current Ratio | 5.89x |
|---|---|
| Quick Ratio | 4.73x |
| Debt / Equity | 0.16x |
| Interest Coverage | -32.62x |
Returns and Efficiency
Return on invested capital is -29.23% over the last 12 months, against a 5-year average of -21.99%.
| Return on Equity (ROE) | -34.92% |
|---|---|
| Return on Assets (ROA) | -24.24% |
| Return on Invested Capital (ROIC) | -29.23% |
| Return on Capital Employed (ROCE) | -27.58% |
| ROE (5Y Average) | -30.64% |
| ROA (5Y Average) | -21.61% |
| ROIC (5Y Average) | -21.99% |
| Asset Turnover | 0.72x |
| Inventory Turnover | 1.57x |
| Receivables Turnover | 3.31x |
| Cash Conversion Cycle | 296 days |
Scores
PRCT has an Altman Z-Score of 4.34, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.34 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $352.30M over the last 12 months is up 17.47% from the 12 months before.
| Revenue | $352.30M |
|---|---|
| Revenue Growth (YoY) | +17.47% |
| Gross Profit | $227.79M |
| Operating Income | -$118.41M |
| Pretax Income | -$114.68M |
| Net Income | -$114.86M |
| EBITDA | -$103.29M |
| EBIT | -$111.27M |
| Reported EPS (TTM) | -$2.02 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 69.43% of the $473.76M in total assets.
| Cash and Equivalents | $218.37M |
|---|---|
| Total Debt | $51.77M |
| Net Cash | $166.60M |
| Net Cash Per Share | $2.91 |
| Working Capital | $343.84M |
| Shareholder Equity | $328.91M |
| Book Value Per Share | $5.74 |
| Tangible Book Value | $328.41M |
| Tangible Book Per Share | $5.73 |
| Total Assets | $473.76M |
| Total Liabilities | $144.85M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $8.38M of capital spending, operating cash flow left -$85.07M of free cash flow.
| Operating Cash Flow | -$76.69M |
|---|---|
| Capital Expenditures | $8.38M |
| Free Cash Flow | -$85.07M |
| FCF Per Share | -$1.49 |
| Depreciation and Amortization | $7.97M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -33.61%, against a 5-year average of -84.33%.
| Gross Margin | 64.66% |
|---|---|
| Operating Margin | -33.61% |
| Pretax Margin | -32.55% |
| Net Margin | -32.60% |
| EBITDA Margin | -29.32% |
| EBIT Margin | -31.58% |
| FCF Margin | -24.15% |
| Gross Margin (5Y Average) | 54.48% |
| Operating Margin (5Y Average) | -84.33% |
| Net Margin (5Y Average) | -87.86% |
Growth
Revenue grew 60.14% a year over 3 years.
| Revenue Growth (3Y CAGR) | +60.14% |
|---|---|
| Revenue Growth (5Y CAGR) | +109.04% |
| Book Value Per Share Growth (2Y CAGR) | +8.43% |
| Tangible Book Per Share Growth (2Y CAGR) | +8.56% |
Dividends and Yields
PRCT does not pay a dividend. Its free cash flow yield is -6.24%.
| FCF Yield | -6.24% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 12 similar companies, PRCT has the 5th highest P/S.
P/S RatioPeer median 1.9x
ROICPeer median -6.00%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.90%
| P/S Ratio | 3.9x vs 1.9x median |
|---|---|
| ROIC | -29.23% vs -6.00% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +17.47% vs +8.90% median |
Analyst Forecast
Consensus estimates put revenue growth at 24.00% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +24.00% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PRCT
What is PRCT's market cap?
Procept Biorobotics has a market cap of $1.37B. Its enterprise value, which adds debt and subtracts cash, is $1.20B.
How many shares of PRCT are outstanding?
Procept Biorobotics has 57.33M shares outstanding. The count is up 2.87% from a year earlier.
Does PRCT pay a dividend?
No. Procept Biorobotics does not pay a dividend.
How much debt does PRCT have?
Procept Biorobotics has $51.77M of total debt and $218.37M of cash and equivalents, a net cash position of $166.60M.
PRCT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors